Dorsch Marion 4
4 · Blueprint Medicines Corp · Filed Dec 16, 2020
Insider Transaction Report
Form 4
Dorsch Marion
Chief Scientific Officer
Transactions
- Exercise/Conversion
Common Stock
2020-12-14$37.11/sh+4,600$170,706→ 19,850 total - Sale
Common Stock
2020-12-14$119.00/sh−4,600$547,400→ 15,250 total - Exercise/Conversion
Stock Option (Right to Buy)
2020-12-14−4,600→ 48,000 totalExercise: $37.11Exp: 2026-11-21→ Common Stock (4,600 underlying)
Footnotes (2)
- [F1]Effected pursuant to a trading plan adopted on April 3, 2019 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
- [F2]This option was granted on November 21, 2016. This option vested with respect to 25% of the shares underlying the option on November 21, 2017 and vests as to an additional 1/48th of the shares underlying the option each month thereafter.